ONCY
Oncolytics Biotech Inc
0.631$
-1.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +202.3% | -11.9% | -5.8% | +45.0% | +51.6% | +17.2% | -27.5% | -8.3% | -54.6% | +166.5% | +19.2% | -18.9% | -38.7% | +27.8% | -39.1% | +59.3% | -46.1% | +23.0% | -18.1% | +32.2% | +74.7% | +33.6% | -18.6% | +4.0% | -48.0% | -48.5% | |
| – | +288.2% | -15.2% | -44.0% | +148.4% | +63.1% | +19.8% | -30.9% | -9.8% | -47.0% | +168.3% | +19.6% | -18.0% | -39.2% | +27.8% | -39.8% | +61.5% | -46.4% | +23.4% | -18.9% | +31.0% | +78.2% | +33.1% | -20.5% | +7.0% | -50.6% | -50.2% | |
| – | +287.3% | -15.0% | -44.4% | -68.3% | +369.8% | -71.7% | -0.6% | +92.3% | +10.6% | +357.3% | +15.7% | -16.2% | -41.3% | +30.5% | -43.9% | +69.7% | -49.9% | -1.6% | +15.7% | +3.3% | +120.7% | +32.2% | -71.7% | +199.3% | -54.3% | -55.2% | |
| – | +287.3% | -15.0% | -44.4% | +149.5% | +63.4% | +19.1% | -31.7% | -8.7% | -47.3% | +169.2% | +20.1% | -18.8% | -38.9% | +27.8% | -40.5% | +61.1% | -45.8% | -16.2% | +15.7% | +3.3% | +120.7% | +32.2% | -22.1% | +8.6% | -54.3% | -55.2% | |
| – | +597.4% | -30.8% | -49.1% | +32.3% | -25.6% | -0.8% | +77.3% | -4.7% | +7.8% | -24.9% | +339.9% | -80.6% | -18.8% | +135.3% | +81.1% | +77.3% | -84.0% | +8,731.4% | -98.9% | +3,905.4% | -95.7% | +865.9% | -39.8% | -97.1% | +353.3% | +1,056.2% | |
| – | – | – | -100.0% | – | +59.6% | +115.8% | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +235.1% | +48.2% | +13.8% | -2.6% | -25.2% | -21.0% | +56.7% | +7.6% | -8.9% | +15.2% | +68.8% | +7.2% | +21.5% | -9.8% | -61.6% | +84.5% | +4.2% | +23.8% | +76.3% | -16.3% | +60.3% | -33.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +48.5% | -0.8% | +11.6% | +11.1% | -11.1% | +5.5% | -0.6% | +15.4% | -96.4% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +638.3% | +78.9% | -54.8% | -26.6% | +6.2% | +67.6% | +50.1% | +2.0% | +60.7% | -2.4% | -43.5% | +160.1% | +12.1% | -17.6% | -43.8% | -19.7% | +50.2% | +142.5% | -12.1% | +128.0% | -51.5% | +2.0% | +10.7% | +3.9% | +26.2% | +9.9% | |
| – | +602.5% | +283.7% | -45.7% | -29.8% | +7.3% | +78.3% | +54.6% | +7.8% | +60.7% | -2.4% | -43.5% | +160.1% | +12.1% | -17.6% | -43.8% | -19.7% | +50.2% | +28.5% | -46.2% | +357.2% | -78.9% | -0.7% | +46.7% | +7.4% | +57.8% | +25.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | -26.8% | +18.1% | -26.5% | -38.4% | +108.3% | -4.4% | |
| – | +602.5% | +283.7% | -45.7% | -29.8% | +7.3% | +78.3% | +54.6% | +7.8% | +40.6% | +6.7% | -40.6% | +153.7% | +14.3% | -17.6% | -43.8% | -19.7% | +50.2% | -9.5% | -50.4% | -99.8% | +56,782.8% | -67.1% | +279.1% | -52.0% | +0.5% | +342.3% | |
| – | – | -6.3% | +1.2% | +21.3% | +7.8% | +3.2% | +0.0% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +187.5% | -19.9% | +3.8% | +51.1% | +53.5% | +15.8% | -30.7% | -23.8% | -59.7% | +231.8% | +33.7% | -29.6% | -49.9% | +50.2% | -37.8% | +78.6% | -56.7% | -22.5% | -25.2% | -101.7% | – | +45.8% | -26.6% | +4.0% | -78.3% | -187.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -97.0% | +6.4% | +14.4% | +10.3% | +22.5% | +14.5% | +11.1% | +11.3% | +2.3% | +19.3% | +26.5% | +13.5% | +7.3% | +9.8% | +5.2% | +28.2% | +6.5% | +10.4% | +14.9% | +38.2% | +82.2% | +32.7% | +8.4% | +16.5% | +13.1% | +25.3% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.